Gilead Sciences, Inc. (NASDAQ:GILD) is identified as one of the Most Undervalued S&P 500 Stocks to Buy Right Now. Analyst Daina Graybosch from Leerink Partners maintained a Buy rating on the company with a price target of $114 on September 2. Gilead is recognized for its strong position in the HIV prevention market, especially with the success of Descovy.

The company is facing challenges in accessing Yeztugo, but Descovy has shown solid year-over-year sales growth. This growth is expected to continue due to new US Health and Human Services policy requiring coverage without cost-sharing starting in 2025. Analyst Graybosch anticipates some users of Descovy shifting to Yeztugo as access improves, leading to wider market acceptance.

Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company focused on developing medicines for serious diseases like HIV, viral hepatitis, COVID-19, and cancer. Despite its potential as an investment, certain AI stocks are believed to offer greater upside potential with less downside risk.

For those seeking an undervalued AI stock with significant potential from Trump-era tariffs and onshoring trends, a free report on the best short-term AI stock is recommended. To explore further investment opportunities, check out 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. Source: Insider Monkey.

Read more at Yahoo Finance: Leerink Partners Maintains Buy on Gilead Sciences (GILD)